Curated News
By: NewsRamp Editorial Staff
October 26, 2026

HeartBeam Accepted into FDA TAP Pilot for 3D ECG Heart Attack Tech

Discuss on Substack
Original Source

TLDR

  • HeartBeam gained FDA TAP entry for its 3D ECG heart attack assessment, positioning it early in a $15 billion market opportunity.
  • HeartBeam's TAP acceptance gives it dedicated FDA advisors and expedited feedback as it plans a pivotal study for 2027.
  • HeartBeam's portable 3D ECG aims to detect heart attacks outside hospitals, bringing faster cardiac care to more people.
  • HeartBeam's cable-free device collects ECG signals from three directions and synthesizes them into a 12-lead ECG.

Impact - Why it Matters

This news matters because HeartBeam's acceptance into the FDA's TAP Pilot could significantly accelerate the development and regulatory review of its 3D ECG technology for heart attack assessment, potentially bringing a portable, cable-free solution to patients sooner. Heart attacks are a leading cause of death, and the ability to assess them outside traditional medical settings could lead to faster diagnosis and treatment, especially in emergency situations. With a market opportunity estimated at $15 billion for heart attack assessment and over $40 billion for the broader cardiac platform, this milestone positions HeartBeam to capture a substantial share of the cardiac care market. Moreover, the TAP program's access to insurers may help streamline coverage once the technology is approved, improving patient access. For investors, this validates the company's innovative approach and could enhance its growth prospects.

Summary

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care, announced that the U.S. Food and Drug Administration (FDA) has accepted its HeartBeam System into the Total Product Life Cycle Advisory Program (TAP) Pilot. This follows the receipt of Breakthrough Device Designation earlier this month. The TAP program provides dedicated FDA advisors, expedited regulatory feedback, and access to healthcare providers, patient advocacy groups, and insurers to help accelerate development and patient access. The acceptance applies to HeartBeam’s 3D electrocardiogram (ECG) technology being developed to assess potential heart attacks outside traditional medical settings. The company estimates the heart attack assessment market opportunity at approximately $15 billion within a broader cardiac platform opportunity exceeding $40 billion.

HeartBeam expects to seek FDA alignment on its multicenter pivotal study design in the coming months, with patient enrollment anticipated to begin in the first quarter of 2027. The study is intended to support a future regulatory submission expanding the HeartBeam System’s indications to include heart attack assessment. The company is also evaluating eligibility for the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, designed to accelerate Medicare access to eligible Breakthrough devices. The HeartBeam System is not currently cleared for heart attack detection, and TAP participation does not guarantee future FDA authorization or insurance coverage. To view the full press release, visit https://nnw.fm/NdfEK.

HeartBeam, Inc. (NASDAQ: BEAT) is dedicated to transforming the detection and monitoring of critical cardiac conditions. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement. The latest news and updates relating to BEAT are available in the company’s newsroom at https://nnw.fm/BEAT.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, HeartBeam Accepted into FDA TAP Pilot for 3D ECG Heart Attack Tech

Blockchain registration record for this content